Retrospective and Prospective Disease Progression and Quality of Life in XLH
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04049877|
Recruitment Status : Recruiting
First Posted : August 8, 2019
Last Update Posted : August 8, 2019
There is limited empirical data documenting disease progression and impact on quality of life for patients with X-linked hypophosphatemia (XLH). This study seeks to investigate the impact of XLH in adults living in the UK retrospectively and prospectively over a 12 month period, using qualitative interviews, SEIQoL-DW, EQ-5D-5L, SF36 quality of life tools.
XLH is a rare, genetic, chronically debilitating and deforming condition (www.nice.org.uk/guidance/HST8). XLH is characterised by renal phosphate wasting, hypophosphatemia and defective bone mineralisation. The incidence of XLH is reported to be between 1:20,000 and 1:25,000 live births. In the UK, it is estimated that there are around 250 paediatric XLH patients and around 2,500 adult XLH patients (Delmestri,et al [Unpublished report]2018). The clinical phenotype of XLH is varied amongst patients, even among affected members of the same family. This can range from no signs or symptoms, slow growth in children, short stature, bone abnormalities that can affect movement and result in pain, bowed legs and knocked knees (where lower legs are positioned at an outward angle), tooth abscesses and excessive dental caries and hearing loss (adult patients only).
This study will recruit 36 adults living with XLH, who are aged 28 years or over and living in the UK. The study will be advertised by the Sponsor and funder Medialis Ltd and via the patient organisation Metabolic Support UK. All study activities will take place via tele-visits and online questionnaires. The study will last approximately 2 years, allowing for one-year recruitment and a further 12 months to conduct all study visits.
|Condition or disease||Intervention/treatment|
|X-linked Hypophosphatemia (XLH)||Other: None - Observational study|
|Study Type :||Observational|
|Estimated Enrollment :||36 participants|
|Official Title:||Retrospective and Prospective Disease Progression and Quality of Life in X-linked Hypophosphatemia (XLH)|
|Actual Study Start Date :||July 7, 2019|
|Estimated Primary Completion Date :||July 2020|
|Estimated Study Completion Date :||July 2021|
- Other: None - Observational study
None - Observational study
- Schedule for the Evaluation of Individual Quality of Life Direct Weight (SEIQoL-DW) [ Time Frame: 12 months ]Change in quality of life
- Disease progression in adults living with XLH [ Time Frame: 12 months ]Qualitative investigation of disease progression
- EQ- 5D-5L [ Time Frame: 12 months ]Quality of life measure
- SF36 [ Time Frame: 12 months ]Quality of life measure
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04049877
|Oxford, United Kingdom, OX16 0AH|
|Contact: Ravi Jandhyala 44(0)1744865 email@example.com|